Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

This study has been withdrawn prior to enrollment.
(No participants enrolled.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00521092
First received: August 24, 2007
Last updated: May 2, 2014
Last verified: December 2012

August 24, 2007
May 2, 2014
January 2009
October 2010   (final data collection date for primary outcome measure)
  • Response rate [ Time Frame: Up to 11 months ] [ Designated as safety issue: No ]
    The true response rate will be estimated based on the number of responses using a binomial distribution. The confidence intervals for them can be estimated using same distribution. Chi-square test or Fisher's exact test will be used to examine the difference of response rate between the two cohorts and log-rank test for the difference of survival outcomes.
  • Overall survival [ Time Frame: From the date of treatment to date of death, assessed up to 11 months ] [ Designated as safety issue: No ]
    Will be estimated by Kaplan-Meier method.
  • Progression-free survival [ Time Frame: From the date of treatment to date of death or date of disease progression, assessed up to 11 months ] [ Designated as safety issue: No ]
    Will be estimated by Kaplan-Meier method.
  • Levels of plasma-associated HIV-1 RNA viral load and cell-associated KSHV DNA viral load [ Time Frame: Up to 11 months ] [ Designated as safety issue: No ]
    Multivariate analysis will be performed using the Cox proportional hazards model. The effects of CD4+ lymphocyte counts, plasma HIV-1 RNA viral load and KSHV DNA level on the objective response rate will be evaluated using multivariate logistic regression.
  • Overall survival
  • Disease progression-free survival
  • Levels of plasma-associated HIV-1 RNA viral load and cell-associated KSHV DNA viral load
  • Response rate in endemic Kaposi sarcoma (KS), epidemic (AIDS) KS, and in all patients
  • Morphological changes in KS lesions
  • Pharmacokinetic profile of sunitinib malate
  • KSHV gene expression in endemic and epidemic KS lesions in patients in Uganda and Kenya
Complete list of historical versions of study NCT00521092 on ClinicalTrials.gov Archive Site
Changes in CD4+ and CD8+ cell counts, levels of plasma-associated HIV-1 RNA, and cell-associated KSHV DNA load [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
For each treatment cohort and for all groups combined, the Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used to evaluate the changes.
Not Provided
Not Provided
Not Provided
 
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.

PRIMARY OBJECTIVES:

I. Determine the clinical response of sunitinib malate in patients with Kaposi sarcoma (KS) in Uganda and Kenya.

II. Compare clinical response rates in endemic versus epidemic (AIDS) KS. III. Determine the safety and tolerability of sunitinib malate in patients with endemic or epidemic (AIDS) KS.

SECONDARY OBJECTIVES:

I Monitor the impact of sunitinib malate on underlying HIV-1 and Kaposi sarcoma-associated herpesvirus (KSHV) viral infection (HIV-1 plasma RNA and KSHV cell-associated DNA).

II. Evaluate morphological changes in KS lesions after treatment. III. Determine the pharmacokinetic profile of sunitinib malate in patients with KS.

IV Evaluate KSHV gene expression in endemic and epidemic KS lesions in patients in Uganda and Kenya.

OUTLINE: This is a multicenter study. Patients are stratified according to HIV-serostatus (endemic [HIV-seronegative] vs epidemic [HIV-seropositive/AIDS] kaposi sarcoma).

Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

Patients undergo tumor tissue and blood sample collection periodically for correlative and pharmacokinetic studies. Samples are analyzed for CD4 lymphocyte counts, HIV-1 plasma RNA levels, KSHV specific antibodies, expression pattern of KSHV in vitro and in vivo, expression of latently versus lytically expressed genes in tumor tissue, and plasma concentrations of sunitinib malate and its active metabolite, SU12662.

After completion of study treatment, patients are followed every 6 weeks.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • AIDS-related Kaposi Sarcoma
  • Classic Kaposi Sarcoma
  • Drug: sunitinib malate
    Given orally
    Other Names:
    • SU11248
    • sunitinib
    • Sutent
  • Procedure: laboratory biomarker analysis
    Correlative study
  • Procedure: pharmacological study
    Correlative study
    Other Name: pharmacological studies
Experimental: Arm I
Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: sunitinib malate
  • Procedure: laboratory biomarker analysis
  • Procedure: pharmacological study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ECOG performance status 0-1
  • Documented HIV-serostatus [HIV-seronegative (endemic KS) or HIV-seropositive (epidemic/AIDS KS)]
  • No symptomatic organ involvement, visceral crisis, or life-threatening disease (e.g., extensive or symptomatic pulmonary disease or reticuloendothelial system/hepatic involvement) for which aggressive double- or triple-drug combination chemotherapy for urgent cytoreduction is indicated (i.e., doxorubicin hydrochloride, bleomycin, and vinblastine [ABV], BV, or AV)
  • Histologically confirmed Kaposi sarcoma
  • Platelet count > 75,000/uL
  • Life expectancy >= 24 weeks
  • Absolute granulocyte count > 1,000/uL
  • Hemoglobin > 8.0 g/dL OR hematocrit > 24%
  • Serum creatinine =< 2.0 mg/dL
  • AST < 3 times normal
  • Fertile patients must use effective contraception
  • Normal clinical cardiac examination and normotensive (systolic and diastolic BP < 140/90 mm Hg) documented on at least two occasions prior to enrollment
  • Normal ECG including QTc interval < 500 msec
  • Normal echocardiogram prior to enrollment (if feasibly possible)
  • Must be able to swallow study medication
  • No acute infections [Patients with chronic infections (e.g., malaria, tuberculosis, parasitic infections, or hepatitis B or C) that may be active but under treatment are allowed provided all eligibility criteria are met]
  • At least 60 days since prior local treatment modalities (e.g., resection, cryosurgery, radiotherapy, or intralesional therapy) AND treated lesions must have clearly progressed following such therapies if the lesions are to be used as an index lesion
  • No prior systemic anticancer therapy for Kaposi sarcoma
  • Concurrent antiretroviral therapy required for HIV-seropositive patients (Patient must be on a stable regimen 8 weeks prior to study enrollment--An exception may be made for patients who have exhausted or are intolerant to all available regimens)
  • No other concurrent systemic anticancer therapy
  • Patient resides in Uganda or Kenya, East Africa

Exclusion Criteria:

  • Pregnant or nursing
  • Baseline diarrhea >= grade 2 by CTCAE
  • Uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Ongoing or acute active infection
    • Symptomatic congestive heart failure (NYHA class III or IV heart disease)
    • Unstable angina pectoris
  • Uncontrolled intercurrent illness including, but not limited to, any of the following: 1) Cardiac arrhythmia (i.e., history of serious ventricular arrhythmia, ventricular fibrillation, or ventricular tachycardia >= 3 beats in a row OR QTc >= 500 msec) 2) Psychiatric illness or social situation that would limit compliance with study requirements
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00521092
NCI-2009-00229, NCI-2009-00229, CASE 1706 - AMC 049, CDR0000561751, CASE 1706 / AMC 049, 7831, U01CA062502, P30AI036219
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Scot Remick Case Comprehensive Cancer Center
National Cancer Institute (NCI)
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP